Tag: Specialty Pharma

The $356 Billion Margin Trap Is Reshaping Patient Persistence

Post author By Hoot
Post date May 15, 2026

Gross-to-net pressure has become one of the defining commercial realities in specialty pharma. According to Hoot’s latest executive briefing, manufacturers gave back an estimated $356 billion in rebates, government discounts, 340B obligations, and chargebacks before net revenue was ever recognized. That number alone changes how commercial leaders think about growth. The challenge is no longer […]

Tags commercial strategy, gross to net, Patient Education, patient persistence, Specialty Pharma

Why Patient Services Is Breaking as Pharma Goes Direct to Patient

Post author By Hoot
Post date February 2, 2026

Listen to Episode 1: Pharma’s Direct to Patient Pivot: What to Expect in 2026 here. The pharmaceutical industry is moving faster than patients can keep up. Therapies are becoming more specialized. Disease education is more complex. Access models are shifting Direct to Patient. At the same time, physician time is shrinking and patients are being […]

Tags healthcare innovation, patient access, Patient Education, patient engagement, Patient Services, pharma commercialization, Pharma Direct to Patient, pharma leadership, pharma marketing, Specialty Pharma

Direct-to-Patient Is Scaling Fast in Pharma, and Patient Confusion Is the Hidden Risk

Post author By Hoot
Post date January 26, 2026

Enterprise pharma is moving decisively toward direct-to-patient models. This is not a marketing trend or a side project. It is a structural response to access friction, pricing pressure, and the consumerization of healthcare. Patients are behaving more like consumers, distribution models are shifting, and manufacturers are being pulled closer to the patient experience whether they […]

Tags adherence, Direct-to-Patient, Market Access, Patient Education, patient journey, Patient Services, Specialty Pharma